Composition for the treatment of osteoarthritis

(19)

(11)

EP 2 301 554 A8

(12)	CORRECTED EUROPEAN PATENT APPLICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 A1)

(48)	Corrigendum issued on:
	26.10.2011 Bulletin 2011/43

(43)	Date of publication:
	30.03.2011 Bulletin 2011/13

(21)	Application number: 10192184.9

(22)	Date of filing: 17.12.2008

(51)

International Patent Classification (IPC):

A61K 31/7008^(2006.01)
A61P 19/02^(2006.01)

A61K 31/737^(2006.01)

(84)	Designated Contracting States:
	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR
	Designated Extension States:
	AL BA MK RS

(30)

Priority:

28.12.2007 ES 200703459

(62)	Application number of the earlier application in accordance with Art. 76 EPC:
	08868336.2 / 2252302

(71)	Applicant: Bioiberica, S.A.
	08029 Barcelona (ES)

(72)	Inventors:
	Escaich Ferrer, Josep 08029, BARCELONA (ES) Torrent Gibert, Ana Maria 08029, BARCELONA (ES) Ruhi Roura, Ramon 08025, BARCELONA (ES) Dalmau Castañares, Pere 08029, BARCELONA (ES)

(74)	Representative: Sugranes Moliné, Pedro
	Provenza, 304 08008 Barcelona 08008 Barcelona (ES)


	Remarks:
	This application was filed on 23-11-2010 as a divisional application to the application mentioned under INID code 62.

(54)	Composition for the treatment of osteoarthritis

(57) "Pharmaceutical composition for the treatment of osteoarthritis" The present invention relates to pharmaceutical compositions comprising chondroitin sulphate and an amino sugar, wherein the amino sugar is selected from the group consisting of mannosamine, a mannosamine derivative and mixtures thereof. The mannosamine derivative is preferably N-acetylmannosamine. The pharmaceutical compositions may further comprise glucosamine. Said compositions are disclosed for use as a medicament. In particular, said compositions are useful in the treatment or prevention of degenerative joint diseases, preferably of osteoarthritis, in the treatment or prevention of tendon or ligament diseases, disorders or injuries and of immune system diseases, preferably of rheumatoid arthritis.